title: Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon.
abstract: Pegylated or non-pegylated α-interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment with this drug. However, drug eruption or morbilliform eruptions due to interferons have been rarely reported so far. We herein describe a patient who developed morbilliform drug eruption under treatment with pegylated interferon. She was able to continue treatment after switching from pegylated interferon to conventional interferon.
authors.affiliation: Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey.
authors.forename: Sener
authors.initials: S
authors.lastname: Barut
authors.forename: Jale
authors.initials: J
authors.lastname: Yuksek
authors.forename: Engin
authors.initials: E
authors.lastname: Sezer
authors.forename: Ozgur
authors.initials: O
authors.lastname: Gunal
authors.forename: Dogan
authors.initials: D
authors.lastname: Koseoglu
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001415:Back; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D057915:Drug Substitution; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a